Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

533
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
533
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

1.1K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.1K
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

2.2K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
2.2K
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

885
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
885
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

533
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
533
Pathophysiology of Peptic Ulcer Disease: Injurious Factors01:22

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

1.3K
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tracing PFAS Transfer from Mother to the Fetoplacental Unit: Insights from Trimester-Specific Maternal Serum Profiles.

bioRxiv : the preprint server for biology·2026
Same author

Source apportionment of fine particulate matter (PM<sub>2.5</sub>) personal exposures: findings from the Household Air Pollution Intervention Network (HAPIN) study in rural Guatemala.

Journal of exposure science & environmental epidemiology·2026
Same author

Maternal Early Pregnancy Tetrahydrocannabinol (THC) Metabolites Correlate With Newborn Resting-State Functional Connectivity.

Developmental psychobiology·2026
Same author

High-resolution metabolomics of maternal polybrominated diphenyl ethers (PBDE) exposure and preterm birth in the Atlanta African American Maternal-Child Cohort.

Communications medicine·2026
Same author

Gestational Exposure to 10 Classes of Priority Chemicals and Birth Outcomes in the ECHO Cohort.

JAMA network open·2026
Same author

Effects of cooking with liquefied petroleum gas versus biomass on hemoglobin concentrations in pregnant women: a pre-specified exploratory analysis of the HAPIN trial.

Nature communications·2026

Related Experiment Video

Updated: Feb 10, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

1.6K

PFOA and ulcerative colitis.

Kyle Steenland1, Subra Kugathasan2, Dana Boyd Barr1

  • 1Dept. Environmental Health, Rollins School of Public Health, Emory University, United States.

Environmental Research
|May 20, 2018
PubMed
Summary
This summary is machine-generated.

Higher serum perfluoroctanoic acid (PFOA) levels were found in patients diagnosed with ulcerative colitis (UC) compared to Crohn's disease patients or controls. This suggests a potential link between PFOA exposure and UC development.

Keywords:
PFOAUlcerative colitis

More Related Videos

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
09:11

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model

Published on: February 14, 2021

10.6K
Flexible Colonoscopy in Mice to Evaluate the Severity of Colitis and Colorectal Tumors Using a Validated Endoscopic Scoring System
15:49

Flexible Colonoscopy in Mice to Evaluate the Severity of Colitis and Colorectal Tumors Using a Validated Endoscopic Scoring System

Published on: October 16, 2013

32.7K

Related Experiment Videos

Last Updated: Feb 10, 2026

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
06:19

Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis

Published on: May 16, 2025

1.6K
Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model
09:11

Systematic Scoring Analysis for Intestinal Inflammation in a Murine Dextran Sodium Sulfate-Induced Colitis Model

Published on: February 14, 2021

10.6K
Flexible Colonoscopy in Mice to Evaluate the Severity of Colitis and Colorectal Tumors Using a Validated Endoscopic Scoring System
15:49

Flexible Colonoscopy in Mice to Evaluate the Severity of Colitis and Colorectal Tumors Using a Validated Endoscopic Scoring System

Published on: October 16, 2013

32.7K

Area of Science:

  • Environmental Health
  • Gastroenterology
  • Toxicology

Background:

  • Perfluoroctanoic acid (PFOA) is a persistent environmental pollutant found in human serum globally.
  • Previous research indicated a link between PFOA serum levels and ulcerative colitis (UC) but not Crohn's disease.
  • Elevated PFOA levels in drinking water affect millions of Americans.

Purpose of the Study:

  • To investigate if ulcerative colitis (UC) patients have higher serum perfluoroctanoic acid (PFOA) levels compared to Crohn's disease patients and healthy controls.
  • To examine the association between serum PFOA levels and diagnosis of inflammatory bowel disease.

Main Methods:

  • Serum samples from 114 UC patients, 60 Crohn's disease patients, and 75 controls were analyzed for PFOA and other per- and polyfluoroalkyl substances (PFAS).
  • Regression analyses were performed to assess the relationship between PFAS levels and disease diagnosis.
  • Participants were within one year of diagnosis, with a mean age of 17 and mean diagnosis year of 2007.

Main Results:

  • Mean serum PFOA levels were 38% higher in UC patients compared to a combined group of Crohn's disease patients and controls (p=0.01).
  • The odds of UC increased by 1.60 times for each unit increase in log PFOA.
  • In contrast, three other PFAS compounds were found at higher levels in controls and Crohn's disease patients than in UC patients.

Conclusions:

  • Serum PFOA levels are elevated in ulcerative colitis (UC) cases relative to Crohn's disease patients and controls.
  • The findings contrast with the behavior of other PFAS, highlighting PFOA's specific association.
  • A limitation is the inability to confirm if elevated PFOA preceded the UC diagnosis.